

ASX Release

Virtual Lab in Lab agreement secured with US-based Sleep Metrics**Key highlights:**

- **Oventus signs virtual Lab in Lab agreement with US-based sleep diagnostic group, Sleep Metrics**
- **Oregon-based Sleep Metrics provides patients with easy and affordable Obstructive Sleep Apnea testing conducted within their free-standing sleep centres or in the patient's home**
- **Under the agreement, Sleep Metrics is able to offer O2Vent® therapy as a treatment alternative to patients who refuse CPAP or find CPAP therapy challenging**

Brisbane, Australia 22 April 2021: Obstructive Sleep Apnea (OSA) treatment innovator, Oventus Medical Ltd, the Company (ASX: OVN) is pleased to announce that it has signed a new virtual Lab in Lab (VLIL) agreement with US-based sleep diagnostic group, Sleep Metrics.

Sleep Metrics, based in Portland, Oregon, provides at-home sleep studies and Obstructive Sleep Apnea treatments across Oregon and southern Washington. It conducts around 100 in-home sleep studies and treats about 80 CPAP patients per month. Patients are sent a sleep test to their home where they sleep with the device for two nights. A sleep physician then reviews and interprets diagnostic study and sends a report to the patient's doctor with treatment recommendations. Sleep Metrics will be instrumental in supporting the referring physicians and their patients with an alternative treatment if their patient is found to be CPAP intolerant and appropriate for oral appliance therapy.

Under the VLIL agreement, Sleep Metrics will offer O2Vent Optima oral appliances to its non-compliant CPAP patients via the VLIL model. Sleep Metrics will also support the administrative efforts associated with documentation and the scheduling of patients for a dentist-guided home impression session.

This is the fourth VLIL agreement for Oventus and follows the agreement with In Home Oxygen and Medical Equipment - the first VGM member under the marketing agency agreement between Oventus and VGM & Associates - signed last month.

Founder and CEO of Oventus, Dr Chris Hart commented, "We are pleased to have secured this strategically important VLIL agreement with Sleep Metrics. There are tremendous synergies with our VLIL model and Sleep Metrics' existing at-home Obstructive Sleep Apnea testing. Having a company of their calibre adopt our innovative telehealth homecare delivery model will enable more patients than ever to benefit from our technology."

Vice President of Sleep Metrics, Chris Hutcherson added: "We are excited to partner with Oventus Medical to facilitate the offering of the O2Vent Optima oral appliances to patients

challenged with CPAP treatment. The virtual nature of the VLIL model is a welcome offering to our patients and referral sources.”

The virtual Lab in Lab agreement is due to go live next month.

—ENDS—

Authorised for release by the Oventus Medical Ltd Board of Directors

For further information, please visit our website at www.o2vent.com or contact the individuals outlined below.

Dr Chris Hart, Managing Director and CEO: M: +61 409 647 496 or investors@oventus.com.au

Jane Lowe, IR Department: M: +61 411 117 774 or jane.lowe@irdepartment.com.au

About Oventus – see more at www.o2vent.com

Oventus is a Brisbane-based medical device company that is commercialising a unique treatment platform for obstructive sleep apnea (OSA) and snoring. The Company has a collaborative Sleep Physician/Dental strategy that streamlines patients’ access to treatment. The Oventus lab model incorporates digital technology via intra oral scanning to achieve operational efficiencies, accuracy and ultimately patient outcomes.

Unlike other oral appliances, O2Vent Optima devices manage the entire upper airway via a unique and patented built-in airway. O2Vent Optima devices allow for airflow to the back of the mouth while maintaining an oral seal and stable jaw position, avoiding multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while keeping the airway stable.

O2Vent Optima devices are designed for any patient that is deemed appropriate for oral appliance therapy, but especially beneficial for the many people that suffer with nasal congestion, obstruction and mouth breathing. The O2Vent Optima allows nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airway integrated in the appliance.

The ExVent®¹ is a valve accessory that fits into the open airway of the O2Vent Optima device, to augment traditional oral appliance therapy by stabilizing the airway. The ExVent valve contains air vents that open fully on inhalation for unobstructed airflow. The valve closes on exhalation, directing the air through the vents, creating the mild resistance or airway support required to keep the airway stable (known as PEEP, positive end expiratory pressure).

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnea².

¹ The ExVent is yet to be cleared for sale in the US

² Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnea, however many patients have difficulty tolerating CPAP³. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnea treatment⁴. The O2Vent Optima and ExVent provide a discreet and comfortable alternative to CPAP for the treatment of OSA.

³Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003

⁴Sutherland, Kate, et al. "Oral appliance treatment for obstructive sleep apnea: an update." Journal of Clinical Sleep Medicine 10.2 (2014): 215-227.